ImmunoTech Updates on Interim Revenue and Royalty Agreements
AIM ImmunoTech reported progress on royalty generation and trial activities but emphasized the DY15 program is still in preclinical development, with Aritosman for COVID-19 in late-stage trials.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed